transplantation if their evening glucose was >140 mg/dL. After 1 year, none of them had required anti-hyperglycaemic treatment. The control patients (n ¼ 25), however, had received the standard of care [short-acting insulin and/or oral antidiabetics for higher glucose levels (180-250 mg/dL)], and eight of them had required antidiabetic treatment after 1 year. All patients who were not on anti-hyperglycaemic therapy had undergone an oral glucose tolerance test (OGTT) at 3, 6 and 12 months.
The present analysis consisted of performing a follow-up study visit on all available TIP study participants from October 2015 to March 2016. During this visit, for which we obtained approval from the local ethics committee (EK no. 1909/2016), we recorded CVEs, specifically myocardial infarction, coronary angioplasty/artery bypass graft surgery, valve replacement, congestive heart failure, peripheral artery disease and stroke. We also obtained laboratory parameters, height and weight and reevaluated patient demographics. We then divided our patients by the initial study group (basal insulin treatment versus standard-of-care control) and by glycaemic status during the study OGTTs [normal glucose tolerance (NGT; 2-h glucose <140 mg/dL) versus IGT (2-h glucose 140-199 mg/dL) plus diabetes (2-h glucose 200 mg/dL)]. Statistical methods comprised the log-rank test, unpaired two-tailed Student's t-test for continuous variables and unadjusted chi-square test for categorical variables.
We found that among the original 50 TIP study participants who were not lost to follow-up (3 previous treatment and 4 previous control patients), 3 participants had died of CVEs (2 treatment patients and 1 control patient) and 2 CVE-unrelated deaths had occurred (2 control patients). The average follow-up time, i.e. time since patient inclusion in the TIP study (as shown in Table 1 and Figure 1 ), was close to 77 months in the basal insulin treatment group as well as in the standard-of-care control group. During the three post-operative OGTTs, seven V C The Author(s) 2019. Published by Oxford University Press on behalf of ERA-EDTA. This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/licenses/ by-nc/4.0/), which permits non-commercial re-use, distribution, and reproduction in any medium, provided the original work is properly cited. For commercial re-use, please contact journals.permissions@oup.com
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Nephrol Dial Transplant (2020) 35: 544-546 doi: 10.1093/ndt/gfz244 Advance Access publication 5 December 2019 participants had always had NGT (four treatment and three control patients). These participants were significantly younger (by 11.7 years on average), had lower glycated hemoglobin (HbA1c) at the study visit (P ¼ 0.21) and had not experienced any CVEs (shown in Table 1 and Figure 1 ). In contrast, there was no meaningful difference between the treatment versus control group participants regarding CVE occurrence (shown in Figure 1 ). In a three-group comparison of diabetes versus IGT versus NGT, CVE occurrence in diabetics and patients with IGT was similarly worse than in patients with NGT (data not shown).
In conclusion, early basal insulin therapy after kidney transplantation had no beneficial effect on CVEs compared with previous standard of anti-hyperglycaemic care post-transplantation, despite clearly improved glycaemic control during the study period [11] . The fact that TIP study participants with NGT were significantly younger supports the hypothesis that PTDM is seen in older, sicker patients, which is not a novel finding [12] . However, the present analysis is the first to explore hard outcomes in solid organ transplant patients with PTDM by antidiabetic treatment. The findings are unexpected, and although the sample size is too small (by about one half) for the results to reach statistical significance when assuming the estimated hazard rates, they still generate the hypothesis that antidiabetic treatment in PTDM patients might not halt cardiovascular disease. While the PTDM community should have been aware that evidence on the association between treatment and hard outcomes is lacking, most transplant physicians FIGURE 1: Cardiovascular events throughout 7 years of follow-up in kidney transplant recipients who received early basal insulin therapy versus standard of care (left panel) and in the same cohort of patients, but sorted by normal glucose tolerance (NGT) versus by impaired glucose tolerance (IGT) plus diabetes during three oral glucose tolerance tests performed in the first post-operative year (right panel). Cardiovascular events: myocardial infarction, coronary angioplasty/artery bypass graft surgery, valve replacement, congestive heart failure, peripheral artery disease and stroke. Log-rank test for the basal insulin treatment versus standard-of-care control group: P ¼ 0.84. Log-rank test for non-diabetic versus diabetic plus pre-diabetic patients: P ¼ 0.155. seem to assume that treatment of PTDM will be beneficial and treat PTDM anyway. This approach is understandable and may even be mandatory from a clinical standpoint-if anything, to at least prevent the direct consequences of hyperglycaemia. However, further clinical efforts into outcome studies are indispensable, especially in view of the recent consensus guidelines for type 2 diabetics [8, 9] . If knowledge from type 2 diabetics can be transferred to solid organ recipients with PTDM, which has a different pathophysiology than type 2 diabetes [12] , then the most practical approach might be to enrol an adequate number of PTDM patients with various solid organ transplants into outcome studies testing inhibitors of sodium-glucose cotransporter-2 [13] [14] [15] and glucagon-like peptide 1 receptor agonists. Further results on PTDM prevention are also expected from a recently completed clinical trial [NCT03507829 (www.clinicaltrials.gov)] and will be analysed for hard outcomes. 
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